Botox is a brand, not a drug class. The generic medication is onabotulinumtoxinA, one of several botulinum toxin formulations available in the United States. Competitors include Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA), and the newest entrant, Daxxify (daxibotulinumtoxinA). Each has the same fundamental mechanism but different properties that may make one preferable for a given patient.
Same Core, Different Formulations
All these products are type A botulinum toxins. They all block acetylcholine release at the neuromuscular junction. The differences lie in:
Protein structure: The toxin molecule is surrounded by accessory proteins in some formulations (Botox, Dysport, Jeuveau) but not others (Xeomin).
Molecular weight: The total protein complex varies in size, affecting diffusion and potentially immunogenicity.
Stabilizers: Different excipients protect the toxin during storage. Daxxify uses a novel peptide stabilizer instead of human albumin.
Manufacturing: Each product is manufactured differently, producing slightly different final products despite the same active toxin.
| Product | Generic Name | Complexing Proteins | Unique Feature |
|---|---|---|---|
| Botox | OnabotulinumtoxinA | Yes | Market leader, most data |
| Dysport | AbobotulinumtoxinA | Yes | Greater spread, faster onset |
| Xeomin | IncobotulinumtoxinA | No | "Naked" toxin, less immunogenic |
| Jeuveau | PrabotulinumtoxinA | Yes | Cosmetic-only, competitive pricing |
| Daxxify | DaxibotulinumtoxinA | No | Peptide stabilizer, longer duration |
Conversion Ratios
The products are not unit-equivalent. One unit of Botox does not equal one unit of Dysport:
Dysport to Botox: Approximately 2.5-3:1 ratio. Where you would use 20 units of Botox, use 50-60 units of Dysport.
Xeomin to Botox: Approximately 1:1 ratio. Unit-for-unit conversion is standard.
Jeuveau to Botox: Approximately 1:1 ratio. Designed for direct substitution.
Daxxify to Botox: Approximately 1:1 ratio, though optimal conversion is still being refined.
These ratios are approximate. Individual response varies, and some patients require adjustment from calculated conversions.
Onset and Duration Differences
Dysport is often reported to have faster onset than Botox, with patients noticing effect within 24-48 hours versus 3-5 days. The mechanism may involve greater spread from the injection site.
Botox and Xeomin have similar onset profiles, typically 3-7 days to visible effect.
Jeuveau mimics Botox timing closely, as expected from its similar formulation.
Daxxify claims significantly longer duration, with clinical trials showing median effect lasting 6 months rather than the typical 3-4 months. The peptide stabilizer allegedly enhances binding to nerve terminals.
| Product | Onset | Duration |
|---|---|---|
| Botox | 3-7 days | 3-4 months |
| Dysport | 1-3 days | 3-4 months |
| Xeomin | 3-7 days | 3-4 months |
| Jeuveau | 3-7 days | 3-4 months |
| Daxxify | 3-7 days | 6+ months |
The duration advantage of Daxxify, if confirmed in broad clinical practice, would represent a meaningful improvement. Fewer treatments per year means less time and cost, despite higher per-treatment pricing.
Spread Characteristics
Dysport is often described as having greater diffusion from the injection site. This can be advantageous or problematic:
Advantage: Broader areas can be covered with fewer injection points. Forehead treatment may feel more natural with gradual transition zones.
Disadvantage: Greater risk of affecting unintended muscles. Periorbital injection may be more likely to cause ptosis if toxin spreads to the levator.
Botox and Xeomin tend to stay more localized, providing predictable effect at the injection site with less peripheral spread.
The spread characteristics influence injection technique. Experienced injectors adjust their patterns based on which product they are using.
Pricing Considerations
Botox commands premium pricing as the market leader. Brand recognition and extensive safety data justify the cost for many patients.
Dysport typically prices lower per unit, but the conversion ratio means total cost is often similar.
Xeomin often positions as a value option, with competitive per-unit pricing.
Jeuveau entered the market with aggressive pricing aimed at capturing cost-conscious patients. Some practices offer it as their budget option.
Daxxify prices higher per treatment but may cost less annually if fewer treatments are needed.
Price comparison requires calculating total annual cost rather than per-unit cost. A product that costs more per treatment but lasts twice as long may be economical overall.
Switching Between Products
Patients can switch between products for various reasons:
Cost: Seeking lower-priced alternative
Availability: Preferred product out of stock
Response: Inadequate effect from current product
Duration: Wanting longer-lasting results
Resistance: Developing antibodies to one formulation
When switching, the first treatment with a new product is essentially a trial. Prior response to one product does not guarantee equivalent response to another. Dose adjustments are often needed.
Patients with suspected antibody resistance to one product may respond to another. The different protein structures mean antibodies formed against Botox may not neutralize Xeomin, for example.
Choosing a Product
Botox remains the default for many practitioners: most familiar, most data, most patient recognition.
Dysport suits patients wanting faster onset or practitioners comfortable with its spread characteristics.
Xeomin appeals to patients concerned about immunogenicity or seeking value pricing.
Jeuveau serves price-conscious cosmetic patients not requiring therapeutic indications.
Daxxify attracts patients prioritizing duration over per-treatment cost.
The best product is the one that works well for the individual patient in the hands of their specific practitioner. Changing products without clear reason introduces unnecessary variables.
Sources:
- Conversion ratios: Dermatologic Surgery, “Botulinum Toxin Conversion Factors: A Systematic Review”
- Onset and duration comparisons: Aesthetic Surgery Journal, “Comparative Efficacy of Botulinum Toxin Formulations”
- Daxxify clinical trials: Dermatologic Surgery, “DaxibotulinumtoxinA Phase 3 Results for Glabellar Lines”
- Immunogenicity differences: Neurology, “Immunogenicity of Different Botulinum Toxin Preparations”